摘要
目的评价EUS引导下^125Ⅰ粒子植入联合吉西他滨化疗治疗胰腺癌的临床收益疗效。方法41例不能手术切除的胰腺癌患者按完全随机法分为放射性^125Ⅰ粒子植入联合吉西他滨化疗组（21例）和单纯吉西他滨化疗组（20例）。吉西他滨化疗方案为1000mg／m^2，1次／周，静脉滴注，连用3周，休息1周；联合组在^125Ⅰ粒子植入后1周行化疗。评价临床受益疗效（CBR）。结果^125Ⅰ粒子联合吉西他滨化疗组临床受益率为57．1％，达到CBR的中位时间为1周，临床受益疗效持续的中位时间为21周；单纯化疗组分别为25％、4周和15周，两组前2项相差非常显著（P〈0．05），而临床受益疗效持续的中位时间无显著差异（P〉0．05）。结论EUS引导下^125Ⅰ粒子组织间植入联合吉西他滨化疗治疗不能手术切除的胰腺癌的CBR明显优于单纯吉西他滨化疗组。
Objective To investigate the clinical benefit response （CBR） in treating the unresectable pancreatic carcinoma by applying the EUS guided iodine-125 seed implantation combined with chemotherapy of gemcitabine and comparing chemotherapy of gemcitabine alone. Methods Forty-one patients with unresectable pancreatic carcinoma were randomly divided into two groups, one group （Group A） included 21 cases which underwent EUS-guided iodine-125 seed implantation combined with gemcitabine chemotherapy, the rest 20 cases （Group B ） were treated with gemcitabine chemotherapy alone. EUS-guided iodine-125 seed implantation were carried according to the treatment plan system （TPS）, following chemotherapy after 1 week. Gemcitabine was administered at the dose of 1 000 mg/m^2 , through intravenous administration once a week for 3 consecutive weeks every 4 weeks. CBR was assessed. Results CBR of Group A was 57.1% and median time to CBR was 1 week and median duration of CBR was 21 weeks, while CBR of Group B was 25% , and median time to CBR was 4 weeks and median duration of CBR was 15 weeks （ P 〈 0.01 ）. Conclusions EUS- guided iodine-125 seed implantation combined with chemotherapy of gemcitabine was superior to gemcitabine chemotherapy alone in the term of CBR in patients with unresectable pancreatic carcinoma.
出处
《中华胰腺病杂志》
CAS
2008年第5期289-291,共3页
Chinese Journal of Pancreatology
